Medicenna Therapeutics Corp ( (TSE:MDNA) ) has issued an update.
Medicenna Therapeutics Corp has presented promising results from its ABILITY-1 clinical trial at the 2025 AACR Annual Meeting, showcasing the effectiveness of MDNA11 both as a monotherapy and in combination with KEYTRUDA. The trial revealed significant objective response rates in patients with advanced cancers, particularly those resistant to immune checkpoint inhibitors. The data supports the potential of MDNA11 to transform treatment paradigms for difficult-to-treat tumors, with ongoing enrollment in the Phase 2 combination dose expansion arm. The safety profile of MDNA11 remains acceptable, with most adverse events being mild and transient. These findings reinforce MDNA11’s potential as a potent and safe immunotherapy option.
Spark’s Take on TSE:MDNA Stock
According to Spark, TipRanks’ AI Analyst, TSE:MDNA is a Neutral.
Medicenna Therapeutics Corp.’s stock score reflects the company’s financial challenges and negative cash flows. However, positive trial results and strategic initiatives offer potential for future growth. The technical indicators suggest neutral sentiment, while the valuation highlights the speculative nature of the investment. These factors combine to give a modest overall score, emphasizing both the risks and opportunities present for investors.
To see Spark’s full report on TSE:MDNA stock, click here.
More about Medicenna Therapeutics Corp
Medicenna Therapeutics Corp is a clinical-stage immunotherapy company focused on developing Superkines targeting cancer and autoimmune diseases. The company is engaged in the development of MDNA11, a long-acting interleukin-2 super-agonist, which is being evaluated for its efficacy in treating advanced solid tumors.
YTD Price Performance: -32.39%
Average Trading Volume: 50,588
Technical Sentiment Signal: Buy
Current Market Cap: C$84.08M
Find detailed analytics on MDNA stock on TipRanks’ Stock Analysis page.